- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02223806
Active Management of the Third Stage of Labour: Uterine Tonus Assessment by Midwife vs. Patient Self-administration (UTAMP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Postpartum haemorrhage (PPH) is the most common cause of maternal death worldwide. The active management of the third stage of labour (AMTSL) is recognized as an effective strategy to prevent morbidity and mortality associated with PPH and reduce blood loss. AMTSL includes the provision of uterotonic drugs, controlled cord traction, delayed cord clamping and cutting, massage of the uterus, and monitoring of the uterine tonus. Although professional guidelines recommend the steps of AMTSL to be performed by health professionals, the reality of health professionals understaffed hospitals in many low- and middle income countries (LMICs) necessitates task-shifting of the final AMTSL component to patients. Yet, whether uterine tonus assessment yields the same effect when performed by patients and midwives has not been formally evaluated.
Objective: To determine whether there is a difference in effectiveness of routine uterine tonus assessment (every 15 minutes, for 2 hours) when performed by a midwife or self-administered by a patient on the incidence of postpartum haemorrhage . mean blood loss, and other maternal and neonatal outcomes.
Study design: Randomized intervention study. Study population: Pregnant women admitted in the labour to the Korle Bu Teaching Hospital, Accra, Ghana Intervention: the intervention group will receive uterine tonus assessment every 15 minutes for 2 hours by a midwife, the control group will continue the current practice of self-assessment after patient education with regular monitoring of midwives.
Main study parameters/endpoints: post-partum haemorrhage (>500 ml blood loss), severe postpartum haemorrhage (>1000 ml blood loss), mean blood loss, other maternal and neonatal outcomes.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will receive the standard of midwifery and obstetric care, and will have access to emergency obstetric interventions. All steps of the AMTSL will be performed, with the exemption of the last step of uterine tonus assessment for which women will be randomized to receive the intervention or current practice of care. Risk associated with the intervention are discomfort because of an external assessment. Data will be obtained from record books at the ward. Women will be asked for informed consent prior to participation. This study will be approved by the Ethical en Protocol Review Committee of the University of Ghana Medical School and the Medical Ethical Research Committee of the University Medical Center Utrecht.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Accra, Ghana
- Korle Bu Teaching Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Be in labor with an expected vaginal delivery, as assessed by the midwives
- Gestation age ≥ 37 weeks
- Received antenatal instructions on postnatal uterine tonus assessment
- Provided informed consent.
Exclusion Criteria:
- Age <18
- Elective caesarean delivery
- Severe anemia (<8g/dL)
- Placenta praevia
- Anticipated breech delivery
- Referred patients who have not received antenatal care (ANC) uterine tonus assessment instructions
- Multiple Pregnancy
- Intra uterine fetal death
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Self-assessment of uterine tonus
Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
|
Uterine tonus assessment by patient every 15 minutes for 2 hours.
|
Experimental: Midwife uterine tonus assessment
Uterine tonus assessment every 15 minutes for 2 hours by midwive.
|
Uterine tonus assessment every 15 minutes for 2 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postpartum hemorrhage (>500 ml blood loss)
Time Frame: within 24 hours postpartum
|
To determine whether there is a difference in effectiveness of routine uterine tonus assessment (every 15 minutes, for 2 hours) to prevent post-partum hemorrhage (≥500 ml blood loss) when performed by a midwife and self-administered by a patient.
|
within 24 hours postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean blood loss (in ml)
Time Frame: Within 24 hours postpartum
|
Within 24 hours postpartum
|
|
Severe post-partum hemorrhage
Time Frame: Within 24 hours postpartum
|
>1000ml blood loss
|
Within 24 hours postpartum
|
Use of additional uterotonics
Time Frame: Within 24 hours postpartum
|
Within 24 hours postpartum
|
|
Use of other procedures for management of postpartum hemorrhage
Time Frame: Within 24 hours postpartum
|
I.e.
surgery, manual placenta tissue removal
|
Within 24 hours postpartum
|
Late postpartum hemorrhage
Time Frame: From 24 hours and upto one week
|
Based on readmission
|
From 24 hours and upto one week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joyce L Browne, MD, MSc, UMC Utrecht, The Netherlands
- Principal Investigator: Kerstin D Klipstein-Grobusch, PhD MSc, University Medical Center Utrecht, the Netherlands
- Principal Investigator: Nelson Damale, MBChB, Korle-Bu Teaching Hospital, Accra, Ghana
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMC-GH 002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Hemorrhage
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedPostpartum Haemorrhage | Immediate Postpartum HemorrhageFrance
-
University Hospital, Clermont-FerrandUnknownPostpartum Depression | Postpartum Hemorrhage | Postpartum Women | Postpartum Stress | Postpartum AnxietyFrance
-
ResQ Medical LtdNot yet recruitingPPH | Postpartum Hemorrhage \(PPH\) | Postpartum Hemorrhage \(Primary\)Kenya
-
Cairo UniversityUnknownHemorrhage, PostpartumEgypt
-
Columbia UniversityCompletedHemorrhage, PostpartumUnited States
-
Ain Shams Maternity HospitalUnknownHemorrhage PostpartumEgypt
-
Chelsea and Westminster NHS Foundation TrustCompleted
-
Megan LordThermaSENSE CorpCompletedHemorrhage | Vasoconstriction | Hemorrhage, PostpartumUnited States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedImmediate Postpartum HemorrhageFrance
-
Gynuity Health ProjectsAga Khan Health ServicesCompletedPostpartum Hemorrhage (PPH)Afghanistan
Clinical Trials on Patient self-assessment of uterine tonus
-
Abbott Medical OpticsCompleted
-
Abbott Medical OpticsCompleted
-
Ohio State University Comprehensive Cancer CenterRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Institut de Cancérologie de LorraineCompleted
-
University of California, San FranciscoBristol-Myers Squibb FoundationCompletedStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Neoplasm | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal... and other conditionsUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Assistance Publique Hopitaux De MarseilleCompletedVery Preterm Children With Dysexecutive DisordersFrance
-
University of MichiganAssociation of University Radiologists; GE Radiology Research Academic FellowshipCompletedAdenomyosis | Uterine Fibroids | Uterine BleedingUnited States
-
Hospices Civils de LyonCompletedChemotherapy Effect | G-CHOP Chemotherapy | R-CHOP ChemotherapyFrance
-
Sutter HealthGE Healthcare; University of California, Davis; LifeScanCompletedDiabetes Mellitus, Type 2United States